Aspen Pharmacare, a South African pharmaceutical company, has concluded an agreement with Johnson & Johnson to package, sell and distribute the latter’s COVID-19 vaccines in Africa under its own brand.
In a statement announcing the development, Aspen said the deal also allows it to “discuss the expansion of the agreement to include any new versions of the drug substance, such as those developed for new variants or a different formulation for administration as a booster”.
Meanwhile, Johnson and Johnson said the agreement means Aspen can now supply its COVID-19 vaccine under the Aspenovax brand to all 55 African countries and multilateral entities supporting Africa’s vaccination programme.